Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Mast cells, which are abundant in the airways of asthmatic individuals, act as first responders to viral infections by ...

Discover Iovance's Q4'24 revenue growth, Proleukin's impact on Amtagvi's future, and how it faces competition like Obsidian's ...

A new study suggests that semaglutide, a drug commonly used to treat diabetes, may help protect the brain from the effects of ...

Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

Getting seven experiments on the International Space Station requires a really good idea. Like a brand new way to attack tumors—one that you can only make in space.

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...